IM-MV 19-014_007
|
UMCG
|
Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells
|
07-09-2023
|
Vergunning verleend
|
IM-MV 20-002_006
|
Het Nederlands Kanker Instituut
|
Use of autologous patient-derived T cells transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies
|
24-08-2023
|
Vergunning verleend
|
IM-MV 20-005_006
|
Erasmus MC
|
Use of autologous patient-derived T cells transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies
|
24-08-2023
|
Vergunning verleend
|
IM-MV 23-005_000
|
Gezondheidsdienst voor Dieren
|
Het onder praktijkomstandigheden toepassen van Turkey herpesvirus HVT gebaseerde vectorvaccins (Vectormune-HVT-AIV en (Vaxxitek HVT-IBD-H5), met een insert van hemagglutinine (HA) gen van het H5 subtype, in (opfok)leghennen, om de immunologische respons in de tijd vast testellen
|
17-08-2023
|
Vergunning verleend
|
IM-MV 23-011_000
|
AMC
|
Evaluation of safety and efficacy of an intravenous injection of GNT0003, a suspension of recombinant AAV8 viral vector carrying the human UGT1A1 transgene in patients with Crigler-Najjar syndrome
|
|
Vergunning verleend
|